56069-35-3

Basic information

• Product Name: Ethyl 2-chloro-4-hydroxybenzoate
• Synonyms: Ethyl 2-chloro-4-hydroxybenzoate;BENZOIC ACID, 2-CHLORO-4-HYDROXY-, ETHYL ESTER
• CAS NO: 56069-35-3
• Molecular Weight: 200.622
• Mol File: 56069-35-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Ethyl 2-chloro-4-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-chloro-4-hydroxybenzoate(56069-35-3)
• EPA Substance Registry System: Ethyl 2-chloro-4-hydroxybenzoate(56069-35-3)

Safety Data

• Hazardous Substances Data: 56069-35-3(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 3336-16-1 2-chloro-4-hydroxybenzonitrile 
• 56363-84-9 2-chloro-4-hydroxybenzoic acid 

Downstream Products

• 108091-31-2 5-{5-[3-Chloro-4-(4,5-dihydro-2-oxazolyl)phenoxy]pentyl}-3-methylisoxazole 
• 105639-28-9 3-Chloro-4-(4,5-dihydro-oxazol-2-yl)-phenol 
• 439610-84-1 (S)-(+)-1-methylheptyl 4-benzyloxy-2-chlorobenzoate 
• 886447-20-7 4‐benzyloxy‐2‐chlorobenzoyl chloride 
• 205106-53-2 4-(2-bromo-ethoxy)-2-chloro-benzoic acid ethyl ester 

Relevant articles and documents

Design and Structural Optimization of Dual FXR/PPARδActivators

Nonalcoholic steatohepatitis (NASH) is considered as severe hepatic manifestation of the metabolic syndrome and has alarming global prevalence. The ligand-activated transcription factors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) δhave been validated as molecular targets to counter NASH. To achieve robust therapeutic efficacy in this multifactorial pathology, combined peripheral PPAR?-mediated activity and hepatic effects of FXR activation appear as a promising multitarget approach. We have designed a minimal dual FXR/PPARδactivator scaffold by rational fusion of pharmacophores derived from selective agonists. Our dual agonist lead compound exhibited weak agonism on FXR and PPARδand was structurally refined to a potent and balanced FXR/PPARδactivator in a computer-aided fashion. The resulting dual FXR/PPARδmodulator comprises high selectivity over related nuclear receptors and activates the two target transcription factors in native cellular settings.

VASOPRESSIN V1A ANTAGONISTS

The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V 1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.